SCHEMBL5467237

SCHEMBL5467237

CCOC(=O)c1cccc(-n2c(=O)[nH]c3cccc(CO)c3c2=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ GAA P10253 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ ALOX15 P16050 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ MAT2A P31153 1/20 0.47
▸ PRKCA P17252 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ ALOX5 P09917 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HCRTR1 O43613 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ NPBWR1 P48145 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467198 0.85 MAT2A (0.46) SMN1; SMN2GAANPC1ALOX15ALDH1A1
SCHEMBL28496776 0.81 MAT2A (0.65) SMN1; SMN2GAANPC1ALOX15ALDH1A1
SCHEMBL5466837 0.80 TP53 (0.47) SMN1; SMN2GAANPC1ALDH1A1LMNA
SCHEMBL5472911 0.78 SMN1; SMN2 (0.40) SMN1; SMN2GAANPC1ALDH1A1LMNA
SCHEMBL5478383 0.77 KMT2A (0.39) SMN1; SMN2GAANPC1ALDH1A1LMNA
SCHEMBL5474911 0.74 GAA (0.36) SMN1; SMN2GAANPC1ALDH1A1MAT2A
SCHEMBL1357500 0.73 MAT2A (0.54) SMN1; SMN2GAANPC1ALOX15ALDH1A1
SCHEMBL5469005 0.72 KDM4E (0.61) SMN1; SMN2GAANPC1ALDH1A1LMNA
SCHEMBL7823334 0.71 ALDH1A1 (0.67) SMN1; SMN2GAAALOX15ALDH1A1LMNA
SCHEMBL29449818 0.71 ALOX15 (0.65) SMN1; SMN2GAAALOX15ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
EP-1657238-A1 FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010537-A1 Fused pyramidine derivative and use thereof NR5A1, GNRHR, RXFP3 SMN1; SMN2 2437/4885GAA 3884/4885NPC1 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback